 |
|
|
| |
Sofosbuvir and Ribavirin for the Treatment of Chronic HCV With Cirrhosis and Portal Hypertension With and Without Decompensation: Early Virologic Response and Safety
|
| |
| |
Reported by Jules Levin
EASL 2014 April 9-13 London, UK
Nezam Afdhal,1 Gregory Everson,2 Jose Luis Calleja,3 Geoffrey McCaughan,4
William T Symonds,5 Diana Brainard,5 Jill Denning,5 Theo Brandt-Sarif,5 Lindsay McNair,5 John G. McHutchison,5 Sarah Arterburn,5 Jaime Bosch,10 Michael Charlton,6 Rajender Reddy,7 Tarik Asselah,8 Edward Gane,9 Xavier Forns10
1Beth Israel Deaconess Medical Center, Boston, MA, USA; 2University of Colorado Denver, Aurora, USA; 3Hospital Puerta de Hierro, Madrid, Spain; 4Royal Prince Alfred Hospital, University of Sydney, New South Wales, Australia; 5Gilead Sciences, Inc., Foster City, CA, USA; 6Mayo Clinic, Rochester, MN, USA; 7University of Pennsylvania, Philadelphia, USA; 8Hopital Beaujon, INSERM U773 and
University Paris-Diderot, Clichy, France; 9Auckland City Hospital, Grafton, Auckland, New Zealand; 10Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, and Centro de Investigacion Biomedica en Red de Enfermedades Hepáticas y Digestivas, Barcelona, Spain
|
| |
|
|
|
|
|
